Femasys Inc. Common Stock
FEMYFemasys Inc. (FEMY) is a healthcare company focused on developing and commercializing innovative products for women's health. The company's offerings include solutions for fertility preservation, endometrial sampling, and other gynecological procedures, aiming to provide less invasive and more effective treatment options for women's reproductive health.
Company News
Femasys Inc. announced a partnership with Refuah Health Center to expand access to FemaSeed, its intratubal insemination product, as a first-line infertility treatment in community-based care settings. The partnership aims to strengthen Femasys' commercial footprint and accelerate adoption of FemaSeed, which has demonstrated over double the pregn...
Femasys will showcase its FemaSeed Intratubal Insemination technology at the ASRM 2025 Scientific Congress, highlighting a fertility solution that offers higher pregnancy rates compared to traditional intrauterine insemination (IUI).
Femasys introduces a new FemSperm Insemination Prep Kit to enable gynecologists to perform FemaSeed Intratubal Insemination, aiming to make fertility treatments more accessible and provide an alternative to IVF.
Femasys Inc. announced a public offering of up to 22,184,586 shares of common stock and warrants, expecting to raise approximately $8.0 million to fund commercial expansion, product development, and corporate purposes.
Femasys reported 84.8% revenue growth in Q2 2025, achieving key regulatory approvals in Europe and Asia-Pacific, but faces potential cash constraints with limited runway into early Q4 2025.
